William Blair analyst Andy Hsieh noted on Monday that Viking’s results surpassed Wall Street expectations and outperformed ...

Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

Amycretin, meanwhile, is Novo Nordisk’s latest entry into its clinical-stage obesity pipeline and is a co-agonist of GLP-1 and amylin. A long-acting subcutaneous form of the drug suitable for ...

Promising early data from an experimental trial of a new obesity treatment pill has sent shares of Danish pharmaceutical Novo Nordisk skyrocketing, Bloomberg reports. The drug, called amycretin ...

Novo Nordisk stock shot up to a record high Thursday after the drugmaker said its experimental oral weight-loss drug outperformed blockbuster Wegovy in an early-stage study. Please watch the video ...

Novo Nordisk shares take a hit after a report revealed Eli Lilly’s better weight loss drug Wegovy maker Novo Nordisk's shares were down 1.1% after an analysis showed Eli Lilly's Mounjaro leads ...

While the Amycretin data are preliminary, investors were encouraged by the prospects of Novo Nordisk solidifying a best-in-class obesity designation, a desirable status given rising competition.

including cagrisema and amycretin. Novo Nordisk's Diabetes and Obesity Market Dominance and Pipeline Innovation Support a Wide Moat As a pioneer in diabetes care, Novo has been in the business for ...

Novo Nordisk remains the market leader in international ... been initiated with once-weekly subcutaneous and once-daily oral amycretin in people with type 2 diabetes in Q3. And we're anticipating ...